Evidence map›Paper›PMID 40146446›Full record

ArticleClinical rheumatology2025

Characterization of Patients with Macrophage Activation Syndrome Secondary to Systemic Juvenile Idiopathic Arthritis.

Jagoda Rogowska, Jagoda Kubicka, Martyna Grabowska, Grzegorz Mirocha, Justyna Roszkiewicz, Elżbieta Smolewska

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Highlights on the Contribution of Gut Microbiota to Immune-Mediated Diseases in Childhood.Mediterranean journal of hematology and infectious diseases · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jagoda RogowskaDepartment of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Sporna 36/50, 91-738, Lodz, Poland.ORCID http://orcid.org/0009-0004-5995-5802
Jagoda KubickaDepartment of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Sporna 36/50, 91-738, Lodz, Poland.ORCID http://orcid.org/0009-0004-6464-4777
Martyna GrabowskaDepartment of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Sporna 36/50, 91-738, Lodz, Poland.ORCID http://orcid.org/0009-0002-4030-8272
Grzegorz MirochaDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.ORCID http://orcid.org/0009-0006-4621-6247
Justyna RoszkiewiczDepartment of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Sporna 36/50, 91-738, Lodz, Poland. justyna.roszkiewicz@umed.lodz.pl.ORCID http://orcid.org/0000-0003-1487-7156
Elżbieta SmolewskaDepartment of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Sporna 36/50, 91-738, Lodz, Poland.ORCID http://orcid.org/0000-0002-8421-0448

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe study aimed to analyze the clinical and laboratory characteristics of patients with systemic juvenile idiopathic arthritis (sJIA) who developed macrophage activation syndrome (MAS) and identify factors linked to MAS occurrence.

methodsPatients with sJIA, diagnosed based on internationally recognized criteria, participated in the research. Retrospective clinical and laboratory data from inflammatory episodes complicated by MAS were evaluated. The Hemophagocytic Syndrome diagnostic score was calculated to assess its utility on pediatric population.

resultsThe study included 23 patients with systemic juvenile idiopathic arthritis (sJIA), of whom 7 (30%) experienced macrophage activation syndrome (MAS) during their disease course. At the time of admission, patients who developed MAS exhibited elevated liver enzymes: ALT (Median = 43, IQR: 25 - 473 vs. Median = 14, IQR: 12 - 30, p = 0.006) and AST (Median = 66, IQR: 51 - 666 vs. Median = 27, IQR: 25 - 33, p = 0.024). Similarly, during hospitalization, patients with MAS showed significantly higher AST levels (Median = 534, IQR: 111 - 1130 vs. Median = 31, IQR: 26 - 42, p = 0.020) and ALT levels (Median = 160, IQR: 46 - 559 vs. Median = 23, IQR: 14 - 48, p = 0.024). Additionally, they experienced a greater decrease in platelet count (Median = 119, IQR: 39 - 209 vs. Median = 306, IQR: 249 - 457, p = 0.004), higher white blood cell counts (Median = 29, IQR: 17 - 36 vs. Median = 18, IQR: 14 - 26, p = 0.021), and elevated D-dimer levels (Median = 16,800, IQR: 5,190 - 34,000 vs. Median = 1,851, IQR: 1,352 - 2,189, p = 0.006). No association was found between MAS and gender, muscle pain, hemophagocytosis in bone marrow aspirate, erythematous rash, or conjunctivitis. The Hemophagocytic Syndrome diagnostic score (HS score) at the optimal cutoff of 169 achieved a sensitivity of 86% and a specificity of 88%.

conclusionsThe findings underscore the significance of recognizing specific clinical and laboratory indicators, such as thrombocytopenia and elevated markers like D-dimers and liver enzymes, to identify sJIA patients at heightened risk for MAS. Prompt diagnosis and intervention are crucial to improving outcomes in this patient group. Key Points • The study identifies thrombocytopenia, elevated D-dimers, hypertriglyceridemia, and elevated liver enzymes (AST, ALT) as key laboratory predictors of macrophage activation syndrome (MAS) in systemic juvenile idiopathic arthritis (sJIA) patients. • Laboratory abnormalities, including high ferritin levels, thrombocytopenia, and impaired liver function, were highlighted as critical markers for distinguishing MAS from active sJIA. • Clinical factors such as erythematous rash and conjunctivitis were inversely associated with MAS occurrence, aiding differential diagnosis. • The findings emphasize the importance of early detection and routine monitoring of laboratory parameters to prevent delays in MAS diagnosis and improve patient outcome.

Indexed as

Arthritis, JuvenileMacrophage Activation SyndromeAdolescentAlanine TransaminaseAspartate AminotransferasesChildChild, PreschoolFemaleHumansLymphohistiocytosis, HemophagocyticMaleRetrospective StudiesAlanine TransaminaseAspartate AminotransferasesClinical PredictorsInflammatory EpisodesMacrophage Activation SyndromeSystemic Juvenile Idiopathic Arthritis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.